Skip to Content
Global News Select

J&J-Linked Rapport Therapeutics Files For IPO

By Ben Glickman


Johnson & Johnson-linked biopharmaceutical company Rapport Therapeutics on Friday filed for an initial public offering with the Securities and Exchange Commission.

The Boston-based company is looking to develop small-molecule medicines to treat central nervous system disorders. The company is evaluating potential candidates to treat epilepsy, peripheral neuropathic pain and bipolar disorder.

Rapport did not say how many shares it planned sell or give an anticipated price range for the offering. The company has applied to list its shares on the Nasdaq Global Market under the ticker RAPP.

The company was founded in 2022 with the support of Johnson & Johnson Innovation and Third Rock Ventures. Chief Scientific Officer David Bredt previously led neuroscience discovery at Janssen Pharmaceutica, and Rapport has a licensing agreement with Janssen for developing and commercializing certain products created by Bredt and colleagues at Janssen.

Rapport lists Johnson & Johnson Innovation, Cormorant, Fidelity and Third Rock Ventures among its major stockholders.

Goldman Sachs, Jefferies, TD Securities and Stifel Nicolaus are acting as underwriters of the offering.


Write to Ben Glickman at

(END) Dow Jones Newswires

May 17, 2024 16:38 ET (20:38 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Market Updates

Sponsor Center